Establishment Labs Holdings Inc. reported 29,823,470 common shares outstanding as of November 5, 2026. The company's balance sheet shows a stable cash position of $75.8 million as of September 30, 2026, compared to $75.6 million at the end of 2025, while total current assets increased slightly to $255.7 million.
Establishment Labs reported Q3 2026 revenue of $72.0 million, a 33.9% increase year-over-year, driven by 119% growth in the U.S. market. The company achieved its first-ever quarter of positive operating and free cash flow and raised its full-year 2026 revenue guidance to over $274 million.
Term
Q3 2026
“Third-quarter results reflect strong global revenue growth, increasing operating leverage and an important milestone in cash generation as we invest in innovation and commercial expansion.”
Peter Caldini, Chief Executive Officer
“We enter 2027 with a strong financial foundation and with significant opportunities and growth ahead of us, especially in minimally invasive and reconstruction. We expect fiscal 2027 to deliver growth of 25% and positive cash flow, setting the stage for many years to come.”
Establishment Labs Holdings Inc. entered into an amendment to its Master Supply Agreement with NuSil Technology LLC, extending the contract term from December 31, 2026, to December 31, 2031. The agreement secures the supply of medical-grade silicone for the company's products and includes updated terms for pricing, business continuity, and intellectual property.